There is a sentence that gives away Reinilde Heyrman's whole operating system. The goal of strategic planning, she says, is to embed flexibility in a drug-development program. Most strategy language tries to make the future sound obedient. Heyrman's version assumes the future will misbehave. The useful plan is prepared for that.
This is the voice of someone who has spent a career in the long corridor between an interesting scientific idea and a coordinated clinical program. Today Heyrman is Chief Medical Officer of the Medical Department at Medpace, the Cincinnati-based contract research organization she joined in 2017. Before that came established pharmaceutical companies, smaller biotechnology businesses, a consulting practice, operating roles, development roles, and the kind of meetings where the evidence is incomplete but the decision cannot wait forever.
Her public advice is refreshingly free of heroic vocabulary. Plan early. Compare the experts. Listen for what has not been said. Preserve the sponsor's responsibility to decide. Execute. When conditions change, do not cling desperately to the first route. Think through alternatives, including a backup plan for the backup plan. It sounds plain because mature judgment often does.
The education of a standard-setter
Heyrman studied medicine at the University of Antwerp from 1978 to 1985. Years later, when asked about the people who shaped her, she did not begin with famous executives. She remembered a first-grade teacher who encouraged her to be herself, a secondary-school history teacher who pushed her toward better grades, and a genetics professor who fed her interest in science. The sequence is revealing: identity, expectation, curiosity.
When she entered the pharmaceutical industry, two early leaders trusted her with opportunities to learn the commercial side of the work. Their expectations mattered because she did not want to disappoint them. Another manager later took her well outside her comfort zone and became a beloved mentor. Heyrman's description of good role models is a compact management brief: integrity, honesty, skill, belief in people, and high standards for themselves as well as others.
In 2007, while working at Daiichi Sankyo, she was recognized as a Healthcare Businesswomen's Association Rising Star. Her advice at the time was frank. Be passionate about the work. Know your strengths without softening the truth about your limitations. Find ways to keep those limitations from blocking growth. Learn to explain the work in different rooms, especially to senior management. Find a role model and a mentor. Then she added the line that saves all of this from becoming a plaque on a conference-room wall: take the work seriously, but remember that you are flawed and allowed to laugh at yourself.
“Be serious about your work, but accept that you are a human being with inherent flaws: there is nothing wrong with laughing at yourself.”
A career across the seams
By the late 1990s, Heyrman was an associate director at Pharmacia & Upjohn. She moved through clinical-research leadership at Sankyo and Daiichi Sankyo, progressing from director to senior director and then vice president. Public regulatory records put her in the room as an executive clinical-development representative in discussions with the US Food and Drug Administration. Her publication record shows another side of the same period: work on study design, combination therapies, pediatric modeling, and the interpretation of clinical results.
The titles changed, but the seam she worked across remained consistent. Science had to meet regulation. A development concept had to meet an operational calendar. Specialist advice had to meet a company decision. Data had to become a story coherent enough for colleagues, reviewers, investigators, and investors to understand.
- 2001-2012Sankyo and Daiichi Sankyo - clinical research and development leadership.
- 2012-2014Ikaria - Vice President and Chief Clinical Development Officer.
- 2014-2015Bellerophon Therapeutics - Chief Clinical Development Officer and Secretary.
- 2015-2016Insmed - Senior Vice President, Clinical Development and Operations.
- 2016-2017Heyrman Pharma Consulting - Principal.
- 2017-presentMedpace - from Vice President to Chief Medical Officer.
In 2012 she left Daiichi Sankyo for Ikaria as Chief Clinical Development Officer. Two years later, she held the same core responsibility at Bellerophon Therapeutics, where she also served as secretary. Insmed recruited her in 2015 to oversee clinical development and operations, including the development and registration readiness of its pipeline. A year as principal of Heyrman Pharma Consulting followed. Then came Medpace.
The moves form more than a ladder. They cross the border between a sponsor and its service partners, between a large organization and an emerging one, and between advising and owning. Earlier in her career, Heyrman spoke about why pharmaceutical companies outsource critical development functions. Later, she joined a CRO and ultimately became its chief medical officer. She had seen the relationship from both sides of the table.
The detective in the strategy room
Heyrman's framework for emerging biotechnology teams begins before the protocol hardens. Strategy should give a company a shared account of its goals, sequence, resources, risks, and regulatory route. It also helps a young company explain itself to potential investors. Yet she does not treat the strategy as a monument. Its highest purpose is flexibility.
This is where partners enter. A capable partner can identify landmines early and connect choices across manufacturing, nonclinical work, clinical design, and regulatory expectations. But advice creates a new problem: experts disagree. Each adviser carries an agenda, consciously or otherwise. The sponsor must compare recommendations, read between the lines, remain open to unwelcome information, and still make the final decision. Heyrman calls the process a kind of detective work in search of the truth.
“The ultimate goal of strategic planning is to embed flexibility in your drug development program.”
The detective image is better than the usual image of the visionary. A detective does not bend the facts toward a preferred answer. She builds a theory, tests it against contrary evidence, notices omissions, and updates. The job contains conviction, but conviction remains answerable to what the investigation reveals.
There is also an important boundary around partnership. Medpace's medical-affairs model describes a team that works alongside the sponsor across medical, regulatory, and operational questions. Heyrman's own language stresses responsibility, ownership, and becoming a seamless extension of the sponsor team. Extension does not mean substitution. The sponsor retains the ultimate call.
Execution, without theater
Planning can become a socially acceptable way to postpone responsibility. Heyrman's remedy is execution. The plan must specify what happens, when it happens, and how the team will accomplish it. A strategy without those answers may be thoughtful, beautifully formatted, and useless.
Her emphasis on contingency planning fits this view. Backups are not signs that a team lacks confidence. They are evidence that the team has taken reality seriously. The underlying culture matters too: streamlined decisions, permission to propose alternate scenarios, and enough scientific grounding to distinguish a productive pivot from nervous motion.
This is also why selection matters. Heyrman says Medpace works where its teams believe they can add value. The point is not ubiquity. It is fit: the scientific question, the sponsor, the capabilities, and the responsibility have to line up. Saying yes creates an obligation to own the work, not merely to occupy a place in the workflow.
The transferable lesson
Clinical development is a specialized world, but Heyrman's operating principles travel well. Any difficult project contains partial knowledge, competing advisers, scarce time, handoffs, and decisions whose consequences arrive later. The leader's job is not to perform certainty. It is to create a system in which uncertainty can be handled without dissolving accountability.
Start close to the evidence. Make the goal legible. Surface the assumptions. Invite expert disagreement before the deadline becomes a crisis. Separate advice from authority. Give the team alternate routes. Make the owner of the next decision visible. Then execute and let the new evidence change the plan.
Heyrman's story adds one more condition: remain human enough to learn. Her best mentors combined confidence in her with pressure to stretch. Her advice combines self-knowledge with communication, seriousness with humor. That balance may be the quiet source of her approach to plans as well. A rigid plan needs to look infallible. A flexible one can admit what it does not yet know and keep moving.
After decades in development, operations, and medical leadership, Heyrman's public philosophy fits on a small card. Begin with the science. Plan early. Build room for the world to surprise you. Listen carefully, especially when the advice is uncomfortable. Keep the decision where it belongs. Make the plan executable. And when the route closes, do not mourn the map. Choose the next road.
Continue reading